Bispecific Molecule Stabilizing Composition

A pharmaceutical composition which is preferably liquid comprising

• (a) a bispecific antigen-binding molecule comprising at least three domains, wherein:
• a first domain binds to a target cell surface antigen, wherein the target cell surface antigen is a tumor antigen;
• a second domain binds to an extracellular epitope of the human and/or the Macaca CD3 chain;
• and
• a third domain comprises two polypeptide monomers, each comprising a hinge, a CH2 domain and a CH3 domain, wherein said two polypeptide monomers are fused to each other via a peptide linker, and wherein said third domain comprises in an amino to carboxyl order:
• hinge-CH2-CH3-linker-hinge-CH2-CH3;
• wherein the concentration of the bispecific antigen-binding molecule is 8 to 35 mg/ml;
• (b) at least one buffer agent;
• (c) at least one saccharide;
• and
• (d) at least one stabilizing agent selected from Ethylenediaminetetraacetic acid (EDTA), Diethylenetriaminepentetic acid (DTPA), and citric acid, wherein the stabilizing agent is present in a concentration in the range of 0.005% to 0.25% (w/v), preferably 0.01 to 0.2% (w/v);
• and wherein the pH of the pharmaceutical composition is in the range of 4.0 to 6.0.